Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joshua Press

Obstetrics & Gynecology Seattle, WA Medical Doctor

NPI 1740475383 CMS profile 306575

1101 Madison St., Suite 1500, Seattle, WA 98104

Open in the dashboard

General payments

$115,209

155 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$402,148 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Joshua Press of Seattle, WA is reported in the CMS Open Payments database as having received $115,209 across 155 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $402,148 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Obstetrics & Gynecology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $233 6
2024 General $23,295 31
2023 General $27,068 26
2022 General $7,528 24
2021 General $12,107 19
2020 General $8,984 8
2019 General $35,992 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joshua Press
  • Obstetrics & Gynecology median
  • Middle half of Obstetrics & Gynecology
  • National median

In program year 2025, general payments to Joshua Press were reported at $233. Among 21,306 Obstetrics & Gynecology profiles paid that year, the median was $158 and the middle half received between $51 and $401.

Show as a table
Year Joshua Press Obstetrics & Gynecology median Middle half National median
2019 $35,992 $172 $62–$391 $163
2020 $8,984 $94 $36–$222 $114
2021 $12,107 $136 $42–$369 $132
2022 $7,528 $160 $50–$433 $149
2023 $27,068 $169 $56–$423 $160
2024 $23,295 $152 $50–$371 $164
2025 $233 $158 $51–$401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AstraZeneca Pharmaceuticals LP $99,663 110 payments
  2. GlaxoSmithKline, LLC. $11,428 14 payments
  3. Intuitive Surgical, Inc. $1,125 3 payments
  4. Stryker Corporation $1,105 6 payments
  5. Clovis Oncology, Inc. $598 4 payments
  6. AbbVie, Inc. $336 4 payments
  7. Myriad Genetic Laboratories, Inc. $244 2 payments
  8. TESARO, Inc. $169 2 payments
  9. Genentech USA, Inc. $145 1 payment
  10. Agios Pharmaceuticals, Inc. $125 1 payment
  11. Other $271 8 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $82,270 30 payments
  2. Consulting Fee $16,250 8 payments
  3. Travel and Lodging $9,868 40 payments
  4. Food and Beverage $5,788 74 payments
  5. Education $1,033 3 payments
Products named General payments · program years 2019–2025
  1. LYNPARZA $99,401 106 payments
  2. JEMPERLI $11,158 11 payments
  3. SPY-PHI SYSTEM $1,105 6 payments
  4. DAVINCI XI $1,000 1 payment
  5. Rubraca $328 3 payments
  6. ELAHERE $322 3 payments
  7. ZEJULA Oncology $314 5 payments
  8. ZEJULA Oncology $292 3 payments
  9. MyChoice CDx $149 1 payment
  10. Avastin $145 1 payment
  11. Other $774 16 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

159

Median for Gynecological Oncology: 95

Drug cost

$208,254

Median for Gynecological Oncology: $4,719

Branded share of claims

22%

Median for Gynecological Oncology: 19.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Zejula Niraparib Tosylate Brand 11 $206,527
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 13 $882
Letrozole Generic 19 $427
Oxycodone Hcl Generic 53 $109
Neomycin Sulfate Generic 15 $96
Dexamethasone Generic 11 $73
Ondansetron Odt Ondansetron Brand 11 $58
Metronidazole Generic 15 $49
Ibuprofen Generic 11 $32

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 860 Part D prescribers listed as Gynecological Oncology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$53,627

Medicare's payments for the services billed

Medicare patients

93

Average age 73

Services billed

312

93 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 63%
Cancer 49%
Arthritis 40%
Osteoporosis 26%
Depression 22%
Chronic kidney disease 19%
Diabetes 15%
Ischemic heart disease 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $18,541
  • Merck Sharp & Dohme Corporation $53
$18,594 — —
JEMPERLI
  • GlaxoSmithKline, LLC. $3,921
$3,921 — —
ELAHERE
  • AbbVie, Inc. $203
  • ImmunoGen, Inc. $119
$322 — —
IMFINZI
  • AstraZeneca Pharmaceuticals LP $145
$145 — —
ZEJULA
  • GlaxoSmithKline, LLC. $48
$48 11 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

155 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics & Gynecology in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record